PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Innovate UK awards ten projects over £6m to develop new clinical tools for dementia

Dementia is estimated to affect 850,000 people in the UK and costs the nation around £23bn a year.

Innovate UK has awarded ten new projects over £6m in funding to identify, develop and commercialise biomarker clinical tools and technologies for dementia and neurodegeneration.

Through Innovate UK’s Small Business Research Initiative, the competition will aid in enhancing clinical trials and precision therapies for patients living with dementia.

Estimated to affect 850,000 people in the UK, dementia is a general term for the impaired ability to remember, think or make decisions, which is economically responsible to cost £23bn a year.

Alzheimer’s disease, the most common form of dementia, affects one in 14 people over the age of 65 and one in six people over the age of 80.

In alignment with the Dame Barbara Windsor Dementia Mission, a government-led effort to develop new precision dementia therapies and solutions in the UK, the competition aims to address the complexities of dementia and will empower organisations to develop customised tools using state-of-the-art technologies and repurposed innovations.

Dame Barbara Windsor Dementia Mission co-chairs Nadeem Sarwar and Hilary Evans said: “The… technologies being funded… align with our focus on accelerating biomarker and clinical trial innovation, underpinned by scalable data sciences.”

By addressing the urgent need for improved clinical tools capable of identifying suitable patients for clinical trials and tailoring treatments, the ten projects could revolutionise dementia therapy while leveraging UK life science’s expertise.

The projects selected involve Cumulus Neuroscience, Cortirio, Cambridge Vision Technology, IXICO Technologies, the University of Nottingham, Quantified Imaging, Esya, Fraunhofer UK Research, Cfdx and Occuity and will cultivate artificial intelligence, digital biomarkers, labelling MRI, liquid biopsy and more.

Dr Stella Peace, executive director, healthy living and agriculture domain, Innovate UK, said: “This investment marks a significant step forward in our collective efforts to manage and eventually overcome the challenges posed by dementia” and “will play a pivotal role in shaping the future of dementia therapy, making life better for all”.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026